CN105963310A - Radish thioglycoside composition and application thereof - Google Patents
Radish thioglycoside composition and application thereof Download PDFInfo
- Publication number
- CN105963310A CN105963310A CN201610501285.6A CN201610501285A CN105963310A CN 105963310 A CN105963310 A CN 105963310A CN 201610501285 A CN201610501285 A CN 201610501285A CN 105963310 A CN105963310 A CN 105963310A
- Authority
- CN
- China
- Prior art keywords
- glucorphanin
- compositions
- food
- oligomeric
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 title abstract 2
- 229930182475 S-glycoside Natural products 0.000 title abstract 2
- 150000003569 thioglycosides Chemical class 0.000 title abstract 2
- 240000001970 Raphanus sativus var. sativus Species 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 201000011510 cancer Diseases 0.000 claims abstract description 14
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 6
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims abstract description 6
- QKGJFQMGPDVOQE-UHFFFAOYSA-N Sulforaphen Natural products CS(=O)C=CCCN=C=S QKGJFQMGPDVOQE-UHFFFAOYSA-N 0.000 claims description 32
- QKGJFQMGPDVOQE-HWKANZROSA-N raphanin Chemical compound CS(=O)\C=C\CCN=C=S QKGJFQMGPDVOQE-HWKANZROSA-N 0.000 claims description 32
- 239000000047 product Substances 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 20
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 9
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 6
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 5
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 235000013351 cheese Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 4
- 229960000511 lactulose Drugs 0.000 claims description 4
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 4
- 235000014347 soups Nutrition 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 240000008415 Lactuca sativa Species 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 235000016213 coffee Nutrition 0.000 claims description 3
- 235000013353 coffee beverage Nutrition 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 235000012045 salad Nutrition 0.000 claims description 3
- 235000014438 salad dressings Nutrition 0.000 claims description 3
- 235000011890 sandwich Nutrition 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 235000013555 soy sauce Nutrition 0.000 claims description 3
- 235000013616 tea Nutrition 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 235000015091 medicinal tea Nutrition 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000011805 ball Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 241000220259 Raphanus Species 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000011593 sulfur Substances 0.000 description 16
- 229910052717 sulfur Inorganic materials 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 15
- 229930182470 glycoside Natural products 0.000 description 15
- 230000000968 intestinal effect Effects 0.000 description 15
- -1 Hydrogen thiocyanate-4-mesyl butane Chemical compound 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 6
- 239000012190 activator Substances 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009413 insulation Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 241000219198 Brassica Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000002113 chemopreventative effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 235000011331 Brassica Nutrition 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000011302 Brassica oleracea Nutrition 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 125000004425 isosulfocyanate group Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229960005559 sulforaphane Drugs 0.000 description 2
- 235000015487 sulforaphane Nutrition 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241001465180 Botrytis Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 1
- 244000178937 Brassica oleracea var. capitata Species 0.000 description 1
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 1
- 244000304217 Brassica oleracea var. gongylodes Species 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 240000002514 Cymbidium ensifolium Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229910003978 SiClx Inorganic materials 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002525 isomaltoses Chemical class 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108010058651 thioglucosidase Proteins 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 150000003742 xyloses Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a composition with radish thioglycoside and functional oligosaccharide and application of the composition to preparing chemical cancer prevention and/or treatment products.
Description
Technical field
The invention provides a kind of compositions comprising glucorphanin and functional oligose.The invention still further relates to described group
Compound purposes in the product that preparation is used for cancer chemoprevention and treatment.
Background technology
According to World Health Organization (WHO) 2014 annual report, cancer is whole world morbidity and main causes of death, to people's people's livelihood
Life health causes grave danger, brings heavy financial burden to social development.In the lengthy procedure to anticancer, people
Proposed the concept of cancer chemoprevention in 1976, refer to utilize natural or synthesis chemical substance to prevent, slow down
Or reverse the strategy that cancer occurs to develop.Sulforaphen (Sulforaphane, SFN), also known as Sulforaphane, chemical entitled 1-is different
Hydrogen thiocyanate-4-mesyl butane, belongs to isosulfocyanate, is the strongest anticancer component found in vegetable up to now.
Molecular mechanisms of action for sulforaphen studies and cell experiment result shows further, and sulforaphen is lived by regulation and control II phase enzyme
Property carries out the number of ways such as metabolism detoxification to I phase enzymes metabolism thing or exotic and plays work same or analogous with cancer chemoprevention
With (list of references Myzak MC, Dashwood RH. Cancer Lett., 2006,233:208-18.).
Sulforaphen is as a kind of isosulfocyanate, unstable chemcial property, degradable.Store for convenience, transport and
Using, usual sulforaphen carries out product development and utilization with its precursor forms glucorphanin.In multiple crucifer
Containing glucorphanin, wherein Brassica genus brassica specie mutation Caulis et Folium Brassicae capitatae (Brassica oleracea L.var.italic
Planch.) in sprout glucorphanin content far above other plant and autologous adult tissue (list of references Fahey JW,
Zhang Y, Talalay P. Proc Natl Acad Sci U S A., 1997,94:10367-72.), frequently as plant
Extract source.In plant, the glucorphanin as precursor forms is present in vacuole, with the β being positioned in specific protein body-
Sulfur glycosides enzyme is separated by biofilm system.Plant tissue cell extract or add man-hour destroyed after, glucorphanin contacts with enzyme will
Start sulfur glycosides fast hydrolyzing, obtain comprising multiple biological decomposition product (the list of references Latt é of sulforaphen, Radix Raphani sulfur nitrile
KP, Appel KE, Lampen A. Food Chem Toxicol., 2011,49:3287-309.).Therefore, in order to prevent
Enzymatic degradation loses, and generally in processing technique, the β in plant-sulfur glycosides enzyme is carried out inactivation treatment to reduce Radix Raphani sulfur in prior art
The loss of glycosides.
Although the β in plant-sulfur glycosides enzyme being carried out inactivation be conducive to the preservation of glucorphanin in product, but glucorphanin existing
Need to be converted into sulforaphen competence exertion in organism and go out cancer-resisting activity.According to the literature, glucorphanin mainly passes through root
β-sulfur glycosides enzyme myrosin contained by the beneficial bacteria of intestinal tract such as bulgaricus bacillus, bacillus bifidus group in human body intestinal canal
(myrosinase) it is converted into sulforaphen, and then is absorbed by the body and then plays a series of effect.The present inventor is under study for action
Having been surprisingly found that, due to individual difference, the conversion in the body efficiency of glucorphanin is unsatisfactory and differs greatly, generally can be
About 10%-50% changes, and major part glucorphanin fails to be converted into sulforaphen and absorbed.Therefore, if can improve in intestinal
The efficiency that glucorphanin converts to sulforaphen, potentially contributes to preferably play its anticancer and protective effect on cancer risk.
In order to prevent from glucorphanin extraction process in vitro is degraded loss, prior art before Extraction and enrichment often
Need to take enzyme denaturing to process；On the other hand, for the glucorphanin product of Extraction and enrichment, require consideration for how again to ensure that it is at body
The most effectively play biological activity.China's application 200810210355.8 proposition takes to add exogenous β-sulfur glycosides enzyme and enzyme is lived
The means of agent (such as ascorbic acid), directly increase the total amount of β-sulfur glycosides enzyme in intestinal and are aided with activation β-sulfur glycosides enzyme, promoting to produce
In product, glucorphanin Efficient Conversion in vivo is sulforaphen.But, enzyme is congenital just has unstability as a kind of for β-sulfur glycosides enzyme,
Easily lose activity under room temperature condition.Therefore the condition extracting and storing accordingly traffic requirements of enzyme is the harshest, causes producing containing enzyme
Product are relatively costly and accumulating is inconvenient, it is difficult to extensively apply.
Therefore, prior art in the urgent need to provide a kind of can guarantee that the product effectively converting in glucorphanin body and utilizing and
Method.
Summary of the invention
The present inventor finds in studying for a long period of time: glucorphanin in intestinal to the transformation efficiency of sulforaphen unsatisfactory and
And differ greatly, this can affect effective performance of glucorphanin vivo biodistribution operation, this be before people unwitnessed ask
Topic.In order to solve this problem, the present inventor has attempted multiple way, but effect is the most not ideal enough.In an experiment, invention image
So find that the glucorphanin being mixed into functional oligose is significantly improved to the conversion of sulforaphen in intestinal.Through repeatedly entering
One step experiment and checking, the problems referred to above have had gratifying solution.
To this end, in the first aspect of the invention, it is provided that a kind of compositions, it comprises:
(1) glucorphanin；With
(2) functional oligose.
Inventors have surprisingly discovered that: with the addition of the glucorphanin product after functional oligose after taking in
Intestinal can change into sulforaphen expeditiously.
It is low that functional oligose is that those can not be digested and assimilated, can completely enter the Non-digestible of large intestine by human gastrointestinal tract
Polysaccharide.The non-limiting example of functional oligose includes but not limited to oligofructose, soybean oligo saccharide, oligomeric galactose, low
Xylan, oligomeric isomaltose, oligomeric lactulose, cyclodextrin, oligochitosan, inulin and combinations thereof.
Without being bound by theory, applicant guesses, it is possible to functional oligose is because can not being decomposed by human body and utilizing still
By beneficial bacteria of intestinal tract selective use, thus its possibility affecting beneficial bacteria of intestinal tract quantity and vigor may be not excluded for, probiotic bacteria
Quantity and the change of vigor and then glucorphanin is converted in indirectly improving human body intestinal canal the ability of sulforaphen.Nonetheless,
Above-mentioned imagination is still the supposition afterwards according to experimental result of the present invention.It is true that due to the complexity of internal milieu, merit to be analyzed
Can property oligosaccharide be extremely difficult on the impact of beneficial bacteria of intestinal tract.
In the present compositions, described functional oligose is preferably selected from oligofructose, oligomeric xylose, oligomeric gala
Sugar, oligomeric lactulose and oligomeric isomaltose.In a more preferred embodiment, described functional oligose be oligomeric xylose or
Oligofructose；In a more preferred embodiment, described functional oligose is oligomeric xylose.
In the present compositions, glucorphanin can in the form of a single compound with described functional oligose group
Become compositions；Glucorphanin can also be with the form of plant powder or plant extract and the composition combination of described functional oligose
Thing.Described plant powder or plant extract are the powder from the plant containing glucorphanin or its extract.Preferably, institute
Stating plant is crucifer, particularly Vegetables in Brassica.The example of these plants includes Caulis et Folium Brassicae capitatae, common head cabbage, the garment or robe made of feathers
Caulis et Folium Brassicae capitatae, Chinese cabbage, Brassica oleracea L. var. botrytis L., Caulis et Folium Brassicae junceae, kohlrabi, brussels sprout, Radix Brassicae rapae, Radix Cochleariae officinalis etc..It is highly preferred that glucorphanin can to the west of
Presented in Cymbidium ensifolium (L.) Sw. sprout extract or Caulis et Folium Brassicae capitatae sprout (powder) in the compositions of the present invention.
The compositions of the present invention can also additionally contain myrosin activator.Described myrosin activator is this area
Known, include but not limited to vitamin C (ascorbic acid), zinc ion.Preferably myrosin activator is vitamin C.
In another aspect of the present invention, it is provided that a kind of pharmaceutical composition or food compositions, described compositions except
Outside glucorphanin and functional oligose, it is also possible to additionally contain acceptable on pharmaceutically acceptable excipient or carrier or food adding
Add agent.
The compositions of the present invention may reside in applicable product form, includes but not limited to medicine, food, functional
Food and health food etc..Especially, for food, product form can be selected from following food: food supplement,
Health food, beverage, shake drink, baked product, tea, soup, frumentum, salad, sandwich, salad dressing, soy sauce, coffee,
Cheese, Yoghurt, energy food, and mixture.
Having it is still another aspect of the present invention to provide a kind of method increasing and converting to sulforaphen in glucorphanin body, bag
Include external interpolation functional oligose in glucorphanin product.
Preparing for treatment or the product of prophylaxis of cancer in the compositions that it is still another aspect of the present invention to provide the present invention
Purposes in product.Described cancer selected from selected from the brain cancer, breast carcinoma, colon and rectum carcinoma, skin carcinoma, head and neck cancer, cervical cancer, renal carcinoma,
Pulmonary carcinoma, hepatocarcinoma, ovarian cancer, cancer of pancreas, carcinoma of prostate, thyroid carcinoma, gastric cancer, leukemia, lymphoma, sarcoma and melanoma.Institute
Stating product can be to be the form of medicine or food, and described food includes the form such as health food, functional food.Specifically,
Described food can be to be the food selected from form in detail below: food supplement, health food, beverage, shake drink, bakes product
Product, tea, soup, frumentum, salad, sandwich, salad dressing, soy sauce, coffee, cheese, Yoghurt, energy food, and mixing
Thing.Described medicine or food can be to be following form: soft capsule, hard capsule, drop pill, tablet, granule, pill, injection, mouth
Take liquid, powder, medicated wine, hard sugar, soft sweet, medicinal tea.
In the present compositions, described functional oligose relative to the usage ratio of glucorphanin (based on weight
Than) can be 1:100 to 100:1, preferably 1:50 to 50:1,1:30 to 30:1, more preferably 1:10 to 10:1,1:5 to 5:
1, particularly preferred 1:3 to 3:1.
In the compositions of present aspect, it can be 0.1% to 90%, 0.5% that glucorphanin accounts for the percentage ratio of composition total weight
To 70%, 1% to 50%, preferably 2% to 30%, more preferably 3% to 20%.
The general consumption of the present composition can determine with purpose according to actual needs.For example, it is possible to be agent every day
Amount ensures to take in glucorphanin or the Radix Raphani of the glucorphanin of 0.2mg to 200mg, preferably 0.5mg to 100mg of 0.1 mg to 500mg
Sulfur glycosides or the glucorphanin of the glucorphanin of 1mg to 50mg, more preferably 1mg to 30mg, the glucorphanin of 1mg to 20mg or 2mg are extremely
The glucorphanin of 10mg.
In the present compositions, it is also possible to preferably contain myrosin activator, such as ascorbic acid or zinc from
Son.The consumption of activator ascorbic acid or zinc ion can according to it is generally required to and practical situations determine, such as, this
In bright compositions, the consumption of ascorbic acid can account for the 0.01% to 5% or 0.02% to 2% of composition total weight, preferably 0.05% to
1%, more preferably 0.05% to 0.5%.
Accompanying drawing explanation
Fig. 1 be show compositions A of the present invention, B, C compared with blank group in sulforaphen level in simulated intestinal fluid
Time dependent situation.
Detailed description of the invention
Term " is treated " and is defined as in order to (resist the disease, disease or obstacle are such as referred to as the polytype of " cancer "
One in disease) and process that patient is carried out and nursing, it includes that the compositions using the present invention is with prevention symptom or also
Send out the outbreak of disease or mitigation symptoms or complication or cure or eliminate a disease, disease or obstacle.
Term " prevents " to refer to that it can be applied to disease by using medicine and stop, slowing down or the generation of reverse disease
Any stage before sick generation.
" treatment " in the context of the present invention means to alleviate the symptom relevant to disease or disease, or suppresses these diseases
The development further of shape or deterioration, or prevent or prevent described disease or disease.Similarly, of the present inventionization used herein
" effective dose " or " therapeutically effective amount " of compound refers to alleviate the symptom relevant to described disease or situation wholly or in part or stop
Stop or slow down the development further of these symptoms or deteriorate, or prevention or offer are to described disease or the chemical combination of the prevention of situation
The amount of thing.
Term used herein " cancer " refer to any malignant entity tumor, metastatic tumor or wherein cell division uncontrolled
System and other disease of cell loss differentiation.
The pharmaceutical composition of the present invention can be prepared by routine techniques, such as at Remington:The Science
And Practice of Pharmacy, the 19th edition, the method described in 1995, it is incorporated herein by.Described group
Compound can occur with conventionally form, such as capsule, tablet, aerosol, solution, suspensoid or Topical application forms.
Typical compositions comprises the compounds of this invention and excipient or carrier.Such as, reactive compound is generally and carrier
Mixing, or loaded body dilution, or to be sealed in can be the carrier of ampoule, capsule, sachet, paper or other vessel form
In.When being mixed with carrier by reactive compound, or when carrier serves as diluent, described carrier can be to serve as activation
The solid of the carrier of compound, excipient or medium, semisolid or fluent material.Described reactive compound can adsorb in graininess
(such as it is contained in sachet) on solid carrier.Suitably some examples of carrier are water, saline solution, alcohol, Polyethylene Glycol, gather
Hydroxyl-oxethyl Oleum Ricini, Oleum Arachidis hypogaeae semen, olive oil, gelatin, lactose, hargil, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, straight
The lower alkyl ether of chain starch, magnesium stearate, Talcum, gelatin, agar, pectin, arabic gum, stearic acid or cellulose, silicic acid,
Fatty acid, fatty acid amine, fatty mono glyceride and diglyceride, pentaerythritol fatty ester, polyoxyethylene, hydroxylmethyl cellulose
Element and polyvinylpyrrolidone.Similarly, described carrier or diluent can include any sustained release material known in the art
Material, such as individually glyceryl monostearate or distearin or its mixture with wax.
Described preparation can mix with the adjuvant of discord active component generation adverse reaction.These additives can include
Wetting agent, emulsifying agent and suspending agent, affect the salt of osmotic pressure, buffer agent and/or coloring material, preservative, sweeting agent or seasoning
Agent.If desired, it is also described compositions is carried out sterilizing.
Route of administration can be that reactive compound of the present invention is transported to suitable or desired site of action effectively
Any approach, such as oral, per nasal, pulmonary, suck, subcutaneous, Intradermal, transdermal or parenteral route, such as rectum, reservoir, skin
Under, in intravenous, urethra, intramuscular, intranasal, ophthalmic solution or the approach of ointment, oral route is preferred.
If using solid carrier for Orally administered, then said preparation can be tabletting, puts with powder or pellet form
In hard gelatin capsule, or it can be with the form being lozenge or lozenge.If use liquid-carrier, the most described preparation can be
Syrup, Emulsion, Perle or the form of sterile injectable liquid, such as aqueous or non-aqueous liquid suspension or solution
Agent.
Injectable dosage form generally includes aqueous suspension or Oil suspensions, and it can use suitable dispersant or profit
Prepared by humectant and suspending agent.Injectable form can be solution mutually in or the suspendible prepared with solvent or diluent
The form of agent.Acceptable solvent or carrier include sterilized water, Ringer's solution or normal isotonic saline solution.Or, nothing can be applied
Bacterium oil is as solvent or suspending agent.Preferably, described oil or fatty acid are fixednesies, including natural oil or artificial oil, fat
Fat acid, monoglyceride, diglyceride or triglyceride.
For injection, described preparation can also is that the powder be suitable to above-mentioned appropriate solution reconstruct.These reality
Example include but not limited to cryodesiccated, Rotary drying or be spray-dried powder, amorphous powder, granule, precipitate or
Microgranule.For injection, described preparation can optionally comprise stabilizer, pH adjusting agent, surfactant, biological utilisation
Degree regulator and the combination of these reagent.Described compound can be formulated as carrying out parenteral administration, example by injection
As by injecting or continuous infusion.Unit dosage forms for injection can be in ampoule or in multi-dose container.
The compositions of the present invention is all effective at wide dosage range.Depend on that purposes used (is such as prevented or controls
Treat), the compositions of the present invention can be adjusted in wide in range scope.As it was previously stated, the consumption of compositions can be according to Radix Raphani
The daily intaking amount of sulfur glycosides determines, for example, it is possible to determine the consumption of compositions based on following daily ingestion of dosage: 0.1 mg is extremely
The glucorphanin of 500mg or the glucorphanin of the glucorphanin of 0.1mg to 200mg, preferably 0.5mg to 100mg or 1mg's to 50mg
The glucorphanin of glucorphanin, more preferably 1mg to 30mg, the glucorphanin of 1mg to 20mg or the glucorphanin of 2mg to 10mg.
Generally, can be distributed in unit dosage forms by the present composition, its per unit dosage comprises the Radix Raphani sulfur of effective dose
Glycosides and pharmaceutically suitable carrier.
Generally, be suitable to be administered orally, per nasal, the dosage form of pulmonary or transdermal administration include the glucorphanin of effective dose and pharmaceutically acceptable load
Body or diluent.
Dosage form can be once a day or once a day above the most such as every day twice or use three times a day.Or, dosage form
The most every other day or once in a week can use as required to use less than frequency once a day.
Pharmaceutical composition can be with the form being tablet, capsule, powder, granule, lozenge, liquid or jelly.For oral
Tablet and capsule may be adapted to the form of unit dose medication, and the excipient of routine can be contained, these examples have: combine
Agent such as syrup, Radix Acaciae senegalis, gel, sorbitol, yellow work glue, polyvinylpyrrolidone (PVP)；Filler such as lactose, saccharide, jade
Rice flour, calcium phosphate, sorbitol or glycine；Tablet lubricants such as magnesium stearate, silicon dioxide, Talcum, Polyethylene Glycol or dioxy
SiClx；Disintegrating agent such as potato starch；Acceptable lubricant such as sodium lauryl sulfate.Tablet can be according to known conventional manner
Method in practice is coated.Oral liquid can make watery or oleaginous suspension, solution, Emulsion, syrup or tincture,
May be made as a kind of dry, again modulate with water or other suitable carrier the most again.These liquid preparations can contain
Having the additive of routine, such as suspending agent is (such as: sorbitol, syrup, methylcellulose, glucose syrup, gelatin, hydrogenated food
With oils and fats).Emulsifying agent (such as incubates phospholipid, sorbitol list oleate or Radix Acaciae senegalis), and nonaqueous phase carrier (includes edible oil such as Fructus Pruni
Core oil, the Oleum Cocois of rectification, oils and fats such as glycerol, propylene glycol or ethanol), preservative (such as methyl or propyl p-hydroxybenzoate or
Sorbic acid), also can be containing conventional flavoring agent or coloring agent if needed.
In pharmaceutical composition of the present invention, the percentage ratio of active substance is variable, because medicaments dispensing must be made to make necessarily
The dosage of proper ratio, to obtain preferable curative effect.In a word, pharmaceutical preparation oral administration or the drug administration by injection of the present invention should be by often
70kg body weight 1 to 15 milligram of active substance every day.Following illustrative rather than restrictive be given some implement embodiments.
Below in conjunction with specific embodiment, the present invention is described in further detail, raw materials used as without special theory in following embodiment
Bright, it is the most commercially available, described percentage ratio, without specified otherwise, is i.e. weight percentage.
Embodiment 1:
Preparation rich in Caulis et Folium Brassicae capitatae sprout extractive composition (compositions A) of glucorphanin
(1) mixing: 1800 g Caulis et Folium Brassicae capitatae sprout extract (containing glucorphanin 16.0%) are mixed homogeneously with 200 g oligofructoses,
Obtaining 2 kg Caulis et Folium Brassicae capitatae sprout extractive compositions, wherein glucorphanin accounts for 14.4%.
(2) pack product: by the above-mentioned Caulis et Folium Brassicae capitatae sprout extractive composition rich in glucorphanin by the weight of every bag of 2 g
Subpackage enters in pouch-packaged, obtains powder product.
Embodiment 2:
Preparation rich in Caulis et Folium Brassicae capitatae sprout extractive composition (compositions B) of glucorphanin
(1) mixing: 2 kg Caulis et Folium Brassicae capitatae sprout extract (containing glucorphanin 16.0%) are mixed homogeneously with 1 kg oligomeric xylose, obtains
3 kg are rich in the Caulis et Folium Brassicae capitatae sprout extractive composition of glucorphanin, and wherein glucorphanin accounts for 10.7%.
(2) pack product: by the above-mentioned Caulis et Folium Brassicae capitatae sprout extractive composition rich in glucorphanin by the weight of every bag of 2 g
Subpackage enters in pouch-packaged, obtains powder product, and wherein glucorphanin accounts for 10.7%.
Embodiment 3:
Rich in the Caulis et Folium Brassicae capitatae sprout powder of glucorphanin and the preparation of the compositions (compositions C) of Caulis et Folium Brassicae capitatae sprout extract
(1) mixing: by 200 g Caulis et Folium Brassicae capitatae sprout powder extracts (containing glucorphanin 16%), 800 g Caulis et Folium Brassicae capitatae sprout powder (containing Radix Raphani sulfur
Glycosides 5%), 250 g oligochitosans, 250 g oligofructoses, 250 g oligomeric xyloses, 250 g oligomeric isomaltoses, 10 g ascorbic acid
Mix homogeneously, obtains 2.01 kg rich in the Caulis et Folium Brassicae capitatae sprout powder of glucorphanin and Caulis et Folium Brassicae capitatae sprout extractive composition, wherein Radix Raphani
Sulfur glycosides accounts for 3.58%.
(2) pack product: the above-mentioned Caulis et Folium Brassicae capitatae sprout powder rich in glucorphanin and Caulis et Folium Brassicae capitatae sprout extractive composition are pressed
The weight subpackage of every bag of 2 g enters in pouch-packaged, obtains powder product, and wherein glucorphanin accounts for 3.58%.
Embodiment 4:
In gut simulation liquid, sulforaphen level of conversion measures
Reagent and test sample:
Gut simulation liquid: by 2015 editions " Chinese Pharmacopoeias " two annex method preparation simulated intestinal fluids, take 40 mL simulated intestinal fluids and add
The Lactobacillus bulgaricus of logarithmic (log) phase, elongated bacillus bifidus, Bacillus licheniformis, streptococcus thermophilus and clostridium butyricum each 2 × 107
(each strain 37 DEG C of cultivation 48 h, list of references Cheng DL, Hashimoto in buffering GAM meat soup (pH 7.0) in advance
K, Uda Y. Food Chem Toxicol., 2004,42:351-7.), 37 DEG C of insulations are standby.
Blank group: Caulis et Folium Brassicae capitatae sprout extract, wherein glucorphanin content is 16%.
Compositions A group: with Caulis et Folium Brassicae capitatae sprout extract (glucorphanin content is for 16%): oligofructose=9:1 mixes,
Wherein glucorphanin content is 14.4%.
Compositions B group: with Caulis et Folium Brassicae capitatae sprout extract (glucorphanin content is for 16%): oligomeric xylose=2:1 mixes,
Wherein glucorphanin content is 10.7%.
Compositions C group: with Caulis et Folium Brassicae capitatae sprout mixture (Caulis et Folium Brassicae capitatae sprout extract and Caulis et Folium Brassicae capitatae sprout powder press 1:4 mixing,
Its glucorphanin content is 7.2%): oligosaccharide mixture: vitamin C=100:100:1 mixes, wherein glucorphanin content
It is 3.58 %.
Oligosaccharide mixture: by oligofructose: oligomeric xylose: oligochitosan: oligomeric isomaltose=1:1:1:1 directly mixes
Make.
Operation processes:
(1) blank group: take blank group 0.251 g(and contain glucorphanin 40.1 mg), join in 20 mL gut simulation liquid, in
37 DEG C of insulations, when 0.5 h, 1 h and 2 h, sampling measures wherein sulforaphen content by HPLC, calculates sulforaphen raw
One-tenth rate.
(2) compositions A group: take compositions A group 0.278 g(and contain glucorphanin 40.1 mg), join 20 mL intestinal moulds
Intending in liquid, in 37 DEG C of insulations, when 0.5 h, 1 h and 2 h, sampling measures wherein sulforaphen content by HPLC, calculates
Sulforaphen production rate.
(3) compositions B group: take compositions B group 0.375 g(and contain glucorphanin 40.1 mg), join 20 mL intestinal moulds
Intending in liquid, in 37 DEG C of insulations, when 0.5 h, 1 h and 2 h, sampling measures wherein sulforaphen content by HPLC, calculates
Sulforaphen production rate.
(4) compositions C group: take compositions C group 1.12 g(and contain glucorphanin 40.1 mg), join 20 mL intestinal moulds
Intending in liquid, in 37 DEG C of insulations, when 0.5 h, 1 h and 2 h, sampling measures wherein sulforaphen content by HPLC, calculates
Sulforaphen production rate.
The HPLC assay method of sulforaphen: take sample solution, crosses 0.45 μm filter membrane, carries out HPLC analysis.HPLC condition:
Chromatographic column: company of HuaPu Unitary C18(4.6 mm × 250 mm, 5 μm)；Column temperature: 30 DEG C；Flowing phase: 70% water-30% second
Nitrile；Flow velocity: 0.8 mL/min；Sample size: 10 μ L；Ultraviolet detection wavelength: 245 nm.
Experimental result see table 1 and Fig. 1.
The blank group of table 1. and the relative amount (chromatographic peak area) of sulforaphen in compositions A, B, C group sample solution
From experimental result, rich in the blank group of glucorphanin and compositions group microorganism species in simulation intestinal liquid
Under help, all create sulforaphen, and the prolongation over time of the growing amount of sulforaphen and increase, after reaction 4 hours,
The conversion ratio of blank group has reached 7%, and it is notable to the addition of the conversion ratio of glucorphanin in compositions B of functional oligose and C
Increasing, wherein the conversion ratio increase of the glucorphanin in compositions C group is the most notable, has reached 67%, has carried relative to blank group
High nearly 9 times.Obviously, after with the addition of functional oligose, glucorphanin in intestinal environment to the conversion ratio of sulforaphen
Significantly improve.
Claims (10)
1. a compositions, it comprises:
(1) glucorphanin；With
(2) functional oligose.
Compositions the most according to claim 1, wherein said functional oligose is selected from oligofructose, soybean oligo saccharide, oligomeric
Galactose, oligomeric xylose, oligomeric isomaltose, oligomeric lactulose, cyclodextrin, oligochitosan, inulin and combinations thereof.
3., according to the compositions of claim 1 or 2, wherein said functional oligose is selected from oligofructose, oligomeric xylose, oligomeric
Galactose, oligomeric lactulose and oligomeric isomaltose.
4., according to the compositions of claim 1 or 2, wherein said functional oligose is oligomeric xylose.
5., according to the compositions any one of Claims 1-4, it is pharmaceutical composition or food compositions, the most additionally contains
Acceptable additive on pharmaceutically acceptable excipient or carrier or food.
6. the method converted to sulforaphen in increasing glucorphanin body, including adding functional oligose in glucorphanin.
7. the purposes in the product that preparation is used for treatment or prophylaxis of cancer of the compositions any one of claim 1 to 5.
Purposes the most according to claim 7, wherein said product is medicine or food.
9. according to the purposes of claim 7 or 8, wherein said product is selected from following food: food supplement, health care food
Product, beverage, shake drink, baked product, tea, soup, frumentum, salad, sandwich, salad dressing, soy sauce, coffee, cheese, acid
Cheese, energy food, and mixture.
10., according to the purposes of claim 7 or 8, wherein said product is selected from following form: soft capsule, hard capsule, drip
Ball, tablet, granule, pill, injection, oral liquid, powder, medicated wine, hard sugar, soft sweet, medicinal tea.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610501285.6A CN105963310B (en) | 2016-06-30 | 2016-06-30 | Glucoraphanin composition and application thereof |
| CN202010409751.4A CN111419857B (en) | 2016-06-30 | 2016-06-30 | Glucoraphanin composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610501285.6A CN105963310B (en) | 2016-06-30 | 2016-06-30 | Glucoraphanin composition and application thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010409751.4A Division CN111419857B (en) | 2016-06-30 | 2016-06-30 | Glucoraphanin composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105963310A true CN105963310A (en) | 2016-09-28 |
| CN105963310B CN105963310B (en) | 2020-05-05 |
Family
ID=56954083
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010409751.4A Active CN111419857B (en) | 2016-06-30 | 2016-06-30 | Glucoraphanin composition and application thereof |
| CN201610501285.6A Active CN105963310B (en) | 2016-06-30 | 2016-06-30 | Glucoraphanin composition and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010409751.4A Active CN111419857B (en) | 2016-06-30 | 2016-06-30 | Glucoraphanin composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN111419857B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108294211A (en) * | 2018-02-02 | 2018-07-20 | 云南瑞宝生物科技股份有限公司 | A kind of functional solid beverage and preparation method thereof containing glucorphanin |
| CN108992675A (en) * | 2017-06-07 | 2018-12-14 | 深圳福山生物科技有限公司 | Sulforaphen inclusion compound preparation method |
| CN109381500A (en) * | 2017-08-07 | 2019-02-26 | 深圳福山生物科技有限公司 | A kind of horseradish composition and application thereof |
| CN110664835A (en) * | 2019-12-09 | 2020-01-10 | 中国科学院烟台海岸带研究所 | Compound containing two or more of chitosan oligosaccharide, inulin and ellagic acid and application thereof |
| CN115813970A (en) * | 2022-11-25 | 2023-03-21 | 深圳福山生物科技有限公司 | Stable-release nutrition targeting composition and application thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111419857B (en) * | 2016-06-30 | 2023-08-01 | 深圳福山生物科技有限公司 | Glucoraphanin composition and application thereof |
| CN113057329A (en) * | 2021-04-08 | 2021-07-02 | 成都市三禾田生物技术有限公司 | Glucoraphanin functional food composition |
| CN114657105B (en) * | 2022-04-18 | 2023-07-04 | 江南大学 | Bifidobacterium longum CCFM1206 capable of producing sulforaphane and relieving inflammation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1243747A (en) * | 1997-08-15 | 2000-02-09 | 北京建昊高科技股份有限公司 | Growth-promoting composition for bacteria useful to microecology of intestine |
| CN101332295A (en) * | 2007-06-12 | 2008-12-31 | 卡夫食品集团公司 | Enteric-coated glucosinolates and beta-thioglucosidases |
| CN103458921A (en) * | 2011-02-22 | 2013-12-18 | 考迪尔种子公司 | Spray dried myrosinase and use to produce isothiocyanates |
| CN104342482A (en) * | 2014-10-10 | 2015-02-11 | 哈尔滨工业大学 | Method for detecting activity of myrosinase in probiotics |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552455A (en) * | 2011-10-13 | 2012-07-11 | 宁波海逸生物科技有限公司 | Formula for health care medicine capable of improving nutritional anemia and enhancing immunity |
| CN104922181A (en) * | 2014-12-09 | 2015-09-23 | 林强 | Preparation composition containing broccoli extract with effects of improving immunity and suppressing tumors and preparation method of preparation composition |
| CN111419857B (en) * | 2016-06-30 | 2023-08-01 | 深圳福山生物科技有限公司 | Glucoraphanin composition and application thereof |
-
2016
- 2016-06-30 CN CN202010409751.4A patent/CN111419857B/en active Active
- 2016-06-30 CN CN201610501285.6A patent/CN105963310B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1243747A (en) * | 1997-08-15 | 2000-02-09 | 北京建昊高科技股份有限公司 | Growth-promoting composition for bacteria useful to microecology of intestine |
| CN101332295A (en) * | 2007-06-12 | 2008-12-31 | 卡夫食品集团公司 | Enteric-coated glucosinolates and beta-thioglucosidases |
| CN103458921A (en) * | 2011-02-22 | 2013-12-18 | 考迪尔种子公司 | Spray dried myrosinase and use to produce isothiocyanates |
| CN104342482A (en) * | 2014-10-10 | 2015-02-11 | 哈尔滨工业大学 | Method for detecting activity of myrosinase in probiotics |
Non-Patent Citations (1)
| Title |
|---|
| FULLER, ZOE等: "Influence of cabbage processing methods and prebiotic manipulation of colonic microflora on glucosinolate manipulation of colonic microflora on glucosinolate", 《BRITISH JOURNAL OF NUTRITION》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108992675A (en) * | 2017-06-07 | 2018-12-14 | 深圳福山生物科技有限公司 | Sulforaphen inclusion compound preparation method |
| CN108992675B (en) * | 2017-06-07 | 2021-11-26 | 深圳福山生物科技有限公司 | Sulforaphane clathrate preparation method |
| CN109381500A (en) * | 2017-08-07 | 2019-02-26 | 深圳福山生物科技有限公司 | A kind of horseradish composition and application thereof |
| CN109381500B (en) * | 2017-08-07 | 2021-08-24 | 深圳福山生物科技有限公司 | Horseradish composition and application thereof |
| CN108294211A (en) * | 2018-02-02 | 2018-07-20 | 云南瑞宝生物科技股份有限公司 | A kind of functional solid beverage and preparation method thereof containing glucorphanin |
| CN110664835A (en) * | 2019-12-09 | 2020-01-10 | 中国科学院烟台海岸带研究所 | Compound containing two or more of chitosan oligosaccharide, inulin and ellagic acid and application thereof |
| CN115813970A (en) * | 2022-11-25 | 2023-03-21 | 深圳福山生物科技有限公司 | Stable-release nutrition targeting composition and application thereof |
| CN115813970B (en) * | 2022-11-25 | 2024-05-07 | 深圳福山生物科技有限公司 | Stable-release nutrition targeting composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105963310B (en) | 2020-05-05 |
| CN111419857A (en) | 2020-07-17 |
| CN111419857B (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105963310A (en) | Radish thioglycoside composition and application thereof | |
| CN101829172B (en) | Ganoderma-lucidum medicinal mycoplasm, pharmaceutical preparation, pharmaceutical composition and food composition | |
| CN102987379A (en) | Composition containing barbary wolfberry fruit, chrysanthemum, collagen, lemon and lupeose | |
| CN101904887A (en) | Application of Saussurea involucrata culture in food and anti-inflammatory analgesic medicine | |
| CN107173656A (en) | A kind of Chinese medicine fruits and vegetables probiotics fermented beverage and preparation method thereof | |
| CN101589801A (en) | A kind of manufacture craft of red ginseng honey sheet | |
| CN114128813A (en) | Beverage for relieving alcoholism and protecting liver and promoting vitality of liver and preparation method thereof | |
| CN104799286B (en) | Composition for improving immunity and preparation method of composition | |
| CN102302153A (en) | Health-care composition and preparation method and application thereof | |
| KR20140017932A (en) | Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange | |
| CN106387900A (en) | Composition for regulating blood lipid, blood pressure and blood sugar, as well as application thereof | |
| CN101410101A (en) | Anti-fat-accumulation composition | |
| CN102526346A (en) | Health-care pharmaceutical formulation with immunity-enhancing and senility-delaying functions | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| KR101859166B1 (en) | A composition for removing hangover comprising an herb extract including ginseng | |
| CN102258632A (en) | Anti-acne cream by using camellia oleifera seed oil | |
| CN104857413A (en) | Traditional Chinese medicine composition removing oral malodor and preparation method therefor | |
| CN107136513A (en) | Adjust the health food of colony balance, preparation method and applications in human body | |
| CN103446212B (en) | A kind of liver protection product | |
| CN103446197A (en) | Novel liver protection product | |
| CN106720829A (en) | A kind of polygonatum Solomon's seal sugar-tablet and preparation method thereof | |
| TWI719781B (en) | Use of herb ferment for preparing a composition for preventing obesity | |
| KR102178967B1 (en) | A Composition for preventing or treating menopausal symptoms comprising fermented Puerariae flos extracts | |
| CN115177658B (en) | Composition for reducing blood sugar | |
| CN102160875B (en) | Health product for nourishing blood and moistening skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |